ମେଲଫାଲାନ ଫ୍ଲୁଫେନାମାଇଡ

<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Melphalan flufenamide</nowiki>">Mr. Ibrahem/Melphalan flufenamide
Clinical data
Trade names	Pepaxto
Other names	Melflufen, 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine-4-fluoro-L-phenylalanine ethyl ester, J1
License data	<abbr class="country-name" title="<nowiki>United States</nowiki>">US DailyMed: Melphalan_flufenamide;
Drug class	Alkylating agent
Legal status
Legal status	<abbr class="country-name" title="<nowiki>United States</nowiki>">US: ℞-only;
Pharmacokinetic data
Metabolism	Aminopeptidase hydrolysis, Spontaneous hydrolyisis on N-mustard
Elimination half-life</nowiki>	10 min in vitro
Identifiers
	IUPAC name Ethyl (2S)-2-[[(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate;
Chemical and physical data
Formula	C24H30Cl2FN3O3
Molar mass	498.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N;
	InChI InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1; Key:YQZNKYXGZSVEHI-VXKWHMMOSA-N;

ମେଲଫାଲାନ ଫ୍ଲୁଫେନାମାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Melphalan flufenamide), ପେପାକ୍ସଟୋ ବ୍ରାଣ୍ଡ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମାୟେଲୋମା ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଡେକ୍ସାମେଥାଜୋନ ଭଳି ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହେଲେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୩] ^[୪] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କମ ପ୍ଲାଟେଲେଟ୍, ସ୍ୱଳ୍ପନିଉଟ୍ରୋଫିଲ୍, ସ୍ୱଳ୍ପ ଲୋହିତ ରକ୍ତ କଣିକା, ଅଇ, ତରଳ ଝାଡ଼ା ଏବଂ ଜ୍ୱର ଅନ୍ଥୋଇପାରେ ।^[୩] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନିଆ ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ଆଲକାଇଲେଟିଂ ଏଜେଣ୍ଟ ଯାହା ଡିଏନଏର ସାଧାରଣ ମରାମତିରେ ବାଧା ସୃଷ୍ଟି କରେ ।^[୩]

ମେଲଫାଲାନ ଫ୍ଲୁଫେନାମାଇଡ ଫେବୃଆରୀ ୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୨ ମସିହାରେ ୟୁରୋପରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୩] ^[୫] ଖରାପ ଫଳାଫଳର ଚିନ୍ତା ହେତୁ ନିର୍ମାତା ୨୦୨୧ ଅକ୍ଟୋବରରେ ଔଷଧ ପ୍ରତ୍ୟାହାର କଲେ; ତଥାପି ଏହି ନିଷ୍ପତ୍ତିକୁ ଓଲଟାଇବାକୁ ଚିନ୍ତା କରୁଛନ୍ତି ।^[୬] ୨୦୧୧ ସୁଦ୍ଧା ବ୍ରିଟେନରେ ଏହା ଅନୁମୋଦିତ ନୁହେଁ ।^[୫]

ଆଧାର

↑ Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, et al. (December 2015). "First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies". Investigational New Drugs. 33 (6): 1232–41. doi:10.1007/s10637-015-0299-2. PMID 26553306. S2CID 8207569.
↑ Strese S, Wickström M, Fuchs PF, Fryknäs M, Gerwins P, Dale T, et al. (October 2013).
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ "Pepaxti". EMA. Archived from the original on 1 October 2022. Retrieved 31 October 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Pepaxto- melphalan flufenamide injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
↑ ^୫.୦ ^୫.୧ "Melphalan flufenamide". SPS - Specialist Pharmacy Service. 11 November 2018. Archived from the original on 20 April 2022. Retrieved 31 October 2022.
↑ RPh, Diana Ernst (24 January 2022). "Oncopeptides Reconsiders Pepaxto Withdrawal Following Data Review". MPR. Archived from the original on 20 May 2022. Retrieved 31 October 2022.

[1] Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, et al. (December 2015). "First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies". Investigational New Drugs. 33 (6): 1232–41. doi:10.1007/s10637-015-0299-2. PMID 26553306. S2CID 8207569.

[2] Strese S, Wickström M, Fuchs PF, Fryknäs M, Gerwins P, Dale T, et al. (October 2013).

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ ^୩.୭ "Pepaxti". EMA. Archived from the original on 1 October 2022. Retrieved 31 October 2022.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Pepaxto- melphalan flufenamide injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.

[SPS2022-5] ୫.୦ ^୫.୧ "Melphalan flufenamide". SPS - Specialist Pharmacy Service. 11 November 2018. Archived from the original on 20 April 2022. Retrieved 31 October 2022.

[6] RPh, Diana Ernst (24 January 2022). "Oncopeptides Reconsiders Pepaxto Withdrawal Following Data Review". MPR. Archived from the original on 20 May 2022. Retrieved 31 October 2022.

[୩]

[୪]

[୧]

[୨]

[୫]

[୬]